Key opinion leaders share their thoughts on the prospect of effector cell redirection and cell engagers at Biologics UK: In-Person 2022.

Researchers from ETH Zurich demonstrate the promise of deep learning for predicting antigen specificity.

In this Commentary article, we explore how innovative technologies like expression tags could help to overcome challenges associated with recombinant peptide production. The potential for recombinant production to slash manufacturing costs has made it a focal area of research for companies such as Boehringer Ingelheim.

UCB, Bicycle Therapeutics, and Sanofi share their latest findings in Peptide discovery at Biologics UK 2022.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘Accelerating Antibody Engineering With AI/ML & Advanced Computational Tools and Technologies’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.

As market leaders in the biologics field, there is no sign of demand for antibody-based therapies slowing down any time soon. With exclusive insights from the CRUK-AstraZeneca Antibody Alliance Laboratory, we look towards the future of antibody discovery and optimisation.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Sustainable Synthesis of Therapeutic Oligonucleotides’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.

While membrane proteins are inherently unstable and challenging to work with, Salipro Biotech are focusing on the stabilisation of challenging protein targets for a variety of downstream applications. This Commentary article explores how Salipro’s platform technology enables new opportunities for drug development.